Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CETP | P11597 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1826703 | 1.00 | FFAR3 (0.46) | FFAR3POLBTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1826359 | 1.00 | FFAR3 (0.46) | FFAR3POLBTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL42141 | 0.82 | FFAR3 (0.52) | FFAR3SMN1; SMN2MAPK1CYP2C19CYP3A4 | |
| Hydrochloric Acid SCHEMBL15522635 | 0.80 | FFAR3 (0.50) | FFAR3SMN1; SMN2MAPK1CYP2C19NPSR1 | |
| SCHEMBL9709063 | 0.78 | POLB (0.36) | POLBTDP1CYP2C19 | |
| SCHEMBL818086 | 0.78 | POLB (0.36) | POLBTDP1CYP2C19 | |
| SCHEMBL5590817 | 0.75 | POLB (0.32) | POLBTDP1CYP3A4MEN1KMT2A | |
| SCHEMBL25213839 | 0.74 | FFAR3 (0.72) | FFAR3POLBALDH1A1SMN1; SMN2CYP2C19 | |
| SCHEMBL18449 | 0.74 | FFAR3 (0.72) | FFAR3POLBALDH1A1SMN1; SMN2CYP2C19 | |
| SCHEMBL13341342 | 0.74 | FFAR3 (0.72) | FFAR3POLBALDH1A1SMN1; SMN2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754207-B2 | Process for the preparation of rapamycin derivatives | CADILA HEALTHCARE LIMITED (IN) | 2014-06-17 | — | — | US | disclosed |
| US-20120202988-A1 | PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2012-08-09 | — | — | US | disclosed |
| EP-2480557-A2 | PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES | Cadila Healthcare Limited (IN) | 2012-08-01 | — | — | EP | disclosed |
| WO-2011051960-A2 | PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202988-A1 | PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES | RICTOR, MTOR, RPTOR | FFAR3 2855/4885POLB 4088/4885TDP1 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.